Sfoglia per AUTORE
CARITI G
Collezione ASL Città di Torino

  

Items : 59

Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy. in Pharmaceuticals (Basel, Switzerland) / Pharmaceuticals (Basel). 2022 Mar 15;15(3):355. doi: 10.3390/ph15030355.
2022
ASL Città di Torino

Cusato J; Boglione L; De Nicolò A; Caviglia GP; Mornese Pinna S; Ciancio A; Troshina G; Smedile A; Antonucci M; Avataneo V; Palermiti A; Mula J; Manca A; Cariti G; Cantù M; Saracco GM; Di Perri G; D'Avolio A;

Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. in The American journal of gastroenterology / Am J Gastroenterol. 2021 Jun 1;116(6):1248-1255. doi: 10.14309/ajg.0000000000001147.
2021
ASL Città di Torino

Rinaldi L; Messina V; Di Marco V; Iovinella V; Claar E; Cariti G; Sacco R; De Luca M; Scifo G; Gatti P; Barbarini G; Pace Palitti V; Quartini M; Tundo P; D'Offizi G; Parruti G; di Rosolini MA; Garrucciu G; Cosco L; Benanti F; Gimignani G; Vespasiani Gentilucci U; Di Lorenzo F; D'Antò M; Nevola R; Lupia T; Rosato V; Morbiducci V; Luzzitelli I; et alii...

Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders. in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy / J Infect Chemother. 2020 Jan;26(1):18-22. doi: 10.1016/j.jiac.2019.06.004. Epub 2019 Jul 10.
2020
ASL Città di Torino

Boglione L; Lupia T; Cariti G; Di Perri G;

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study. in Drugs in context / Drugs Context. 2020 Dec 15;9:2020-4-11. doi: 10.7573/dic.2020-4-11. eCollection 2020.
2020
ASL Città di Torino

Sacco R; Messina V; Gentilucci UV; Adinolfi LE; Ascione A; Barbarini G; Barlattani A; Cariti G; Cozzolongo R; Fimiani B; Francavilla R; Furlan C; Garrucciu G; Iovinella V; Rinaldi L; Marignani M; Begini P; Palitti VP; Pellicelli AM; Scifo G; Facciorusso A; Giacomelli L; Shah A; Bertino G; Perazzo S; Bresci G; Izzi A;

Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy. in Le infezioni in medicina / Infez Med. 2019 Sep 1;27(3):239-250.
2019
ASL Città di Torino

Di Perri G; Cariti G;

Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis. in Journal of medical virology / J Med Virol. 2019 Jul;91(7):1329-1334. doi: 10.1002/jmv.25438. Epub 2019 Mar 4.
2019
ASL Città di Torino

Boglione L; Lupia T; Cariti G; Ghisetti V; Milia MG; Burdino E; Di Perri G;

2019
ASL Città di Torino

Di Perri G; Cariti G;

Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs. in Cancer chemotherapy and pharmacology / Cancer Chemother Pharmacol. 2018 Mar;81(3):615-620. doi: 10.1007/s00280-018-3520-0. Epub 2018 Jan 22
2018
ASL Città di Torino

Cusato J; Boglione L; De Nicolò A; Favata F; Ariaudo A; Mornese Pinna S; Guido F; Avataneo V; Cantù M; Carcieri C; Cariti G; Di Perri G; D'Avolio A;

Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. in The Journal of antimicrobial chemotherapy / J Antimicrob Chemother. 2018 Jun 1;73(6):1659-1664. doi: 10.1093/jac/dky053.
2018
ASL Città di Torino

Cusato J; De Nicolò A; Boglione L; Favata F; Ariaudo A; Mornese Pinna S; Carcieri C; Guido F; Avataneo V; Cariti G; Di Perri G; D'Avolio A;

Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy. in Pharmacogenomics / Pharmacogenomics. 2018 Jun 1;19(8):701-707. doi: 10.2217/pgs-2018-0009. Epub 2018 May 23.
2018
ASL Città di Torino

Cusato J; De Nicolò A; Boglione L; Favata F; Ariaudo A; Pinna SM; Carcieri C; Guido F; Cariti G; Di Perri G; D'Avolio A;

Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients. in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases / Infect Genet Evol. 2018 Jun;60:42-47. doi: 10.1016/j.meegid.2018.02.016. Epub 2018 Feb 13.
2018
ASL Città di Torino

Cusato J; De Nicolò A; Boglione L; Favata F; Ariaudo A; Mornese Pinna S; Carcieri C; Guido F; Avataneo V; Cariti G; Di Perri G; D'Avolio A;

Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis. in Journal of medical virology / J Med Virol. 2018 Jun;90(6):1047-1052. doi: 10.1002/jmv.25038. Epub 2018 Mar 15.
2018
ASL Città di Torino

Boglione L; Cariti G; Ghisetti V; Burdino E; Di Perri G;

Combination therapy in chronic hepatitis B: what are the real benefits? in Minerva medica / Minerva Med. 2018 Apr;109(2):69-70. doi: 10.23736/S0026-4806.17.05474-X. Epub 2017 Nov 7.
2018
ASL Città di Torino

Boglione L; Cariti G;

Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. in Archives of virology / Arch Virol. 2018 Apr;163(4):961-967. doi: 10.1007/s00705-017-3684-7. Epub 2018 Jan 9.
2018
ASL Città di Torino

Boglione L; Cusato J; Pinna SM; De Nicolò A; Cariti G; Di Perri G; D'Avolio A;

2018
ASL Città di Torino

De Nicolò A; Boglione L; Cusato J; Fatiguso G; Favata F; Allegra S; Cariti G; Di Perri G; D'Avolio A;

2018
ASL Città di Torino

Boglione L; Pinna SM; Lupia T; Cariti G; Di Perri G;

Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C. in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases / Infect Genet Evol. 2017 Sep;53:195-198. doi: 10.1016/j.meegid.2017.05.026. Epub 2017 Jun 1.
2017
ASL Città di Torino

Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A;

Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3. in European journal of public health / Eur J Public Health. 2017 Oct 1;27(5):938-941. doi: 10.1093/eurpub/ckx025.
2017
ASL Città di Torino

Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A;

Influence of ABCB11 and HNF4? genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. in The Journal of antimicrobial chemotherapy / J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849. doi: 10.1093/jac/dkx237.
2017
ASL Città di Torino

Cusato J; De Nicolò A; Boglione L; Favata F; Ariaudo A; Mornese Pinna S; Guido F; Avataneo V; Carcieri C; Cariti G; Di Perri G; D'Avolio A;

Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. in Journal of viral hepatitis / J Viral Hepat. 2017 Oct;24(10):850-857. doi: 10.1111/jvh.12711. Epub 2017 Apr 25.
2017
ASL Città di Torino

Boglione L; Mornese Pinna S; De Nicolò A; Cusato J; Cariti G; Di Perri G; D'Avolio A;

Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. in Pharmacogenomics / Pharmacogenomics. 2017 May;18(7):607-611. doi: 10.2217/pgs-2016-0040. Epub 2017 Apr 28.
2017
ASL Città di Torino

Cusato J; Boglione L; De Nicolò A; Cardellino CS; Carcieri C; Cariti G; Di Perri G; D'Avolio A;

Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients. in Pharmacogenomics / Pharmacogenomics. 2017 May;18(7):651-661. doi: 10.2217/pgs-2016-0041. Epub 2017 Apr 28.
2017
ASL Città di Torino

Cusato J; Boglione L; De Nicolò A; Imbornone R; Cardellino CS; Ghisetti V; Carcieri C; Cariti G; Di Perri G; D'Avolio A;

Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations. in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver / Dig Liver Dis. 2017 Jun;49(6):705-708. doi: 10.1016/j.dld.2017.01.144. Epub 2017 Jan 17.
2017
ASL Città di Torino

Boglione L; De Nicolò A; Mornese Pinna S; Cusato J; Favata F; Ariaudo A; Carcieri C; Cariti G; Di Perri G; D'Avolio A;

Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases / Infect Genet Evol. 2017 Jul;51:167-172. doi: 10.1016/j.meegid.2017.03.014. Epub 2017 Mar 16.
2017
ASL Città di Torino

Boglione L; Cardellino CS; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A;

Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. in Infection / Infection. 2017 Feb;45(1):103-106. doi: 10.1007/s15010-016-0962-3. Epub 2016 Nov 16.
2017
ASL Città di Torino

Boglione L; Pinna SM; Cardellino CS; De Nicolò A; Cusato J; Carcieri C; Cariti G; Di Perri G; D'Avolio A;

Epidemiology, patient profile, and health care resource use for hepatitis C in Italy. in ClinicoEconomics and outcomes research : CEOR / Clinicoecon Outcomes Res. 2017 Oct 10;9:609-616. doi: 10.2147/CEOR.S136456. eCollection 2017.
2017
ASL Città di Torino

Sangiorgi D; Perrone V; Buda S; Boglione L; Cariti G; Lefevre C; Nappi C; Degli Esposti L;

Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B. in International journal of antimicrobial agents / Int J Antimicrob Agents. 2016 Sep;48(3):324-7. doi: 10.1016/j.ijantimicag.2016.05.016. Epub 2016 Jul
2016
ASL Città di Torino

Boglione L; De Nicolò A; Cusato J; Bonifacio G; Cariti G; Di Perri G; D'Avolio A;

Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all? in Journal of viral hepatitis / J Viral Hepat. 2016 May;23(5):402-3. doi: 10.1111/jvh.12502. Epub 2016 Feb 3.
2016
ASL Città di Torino

Boglione L; Cariti G; Di Perri G; D'Avolio A;

Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia. in Pharmacogenetics and genomics / Pharmacogenet Genomics. 2016 Jun;26(6):307-10. doi: 10.1097/FPC.0000000000000223.
2016
ASL Città di Torino

Cusato J; Boglione L; De Nicolò A; Cardellino CS; Carcieri C; Cariti G; Di Perri G; D'Avolio A;

Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon. in Antiviral research / Antiviral Res. 2016 Dec;136:32-36. doi: 10.1016/j.antiviral.2016.10.011. Epub 2016 Oct 26.
2016
ASL Città di Torino

Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A;

Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. in Journal of viral hepatitis / J Viral Hepat. 2015 Mar;22(3):318-27. doi: 10.1111/jvh.12288. Epub 2014 Jul 24.
2015
ASL Città di Torino

Boglione L; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A;

Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. in International journal of antimicrobial agents / Int J Antimicrob Agents. 2015 Jun;45(6):657-61. doi: 10.1016/j.ijantimicag.2015.01.019. Epub 2015 Ma
2015
ASL Città di Torino

Cusato J; Allegra S; De Nicolò A; Boglione L; Fatiguso G; Abdi AM; Cariti G; Di Perri G; D'Avolio A;

ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie / Biomed Pharmacother. 2015 Feb;69:63-9. doi: 10.1016/j.biopha.2014.11.007. Epub 2014 Nov 15.
2015
ASL Città di Torino

Cusato J; Allegra S; De Nicolò A; Boglione L; Fatiguso G; Cariti G; Ciancio A; Smedile A; Strona S; Troshina G; Rizzetto M; Di Perri G; D'Avolio A;

Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie / Biomed Pharmacother. 2015 Feb;69:47-55. doi: 10.1016/j.biopha.2014.10.030. Epub 2014 Nov 6.
2015
ASL Città di Torino

Allegra S; Cusato J; De Nicolò A; Boglione L; Gatto A; Cariti G; Di Perri G; D'Avolio A;

Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy. in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases / Clin Microbiol Infect. 2015 Feb;21(2):205.e1-3. doi: 10.1016/j.cmi.2014.07.009. Epub 2014 Oct 29.
2015
ASL Città di Torino

Boglione L; De Nicolò A; Cardellino CS; Ruggiero T; Ghisetti V; Cariti G; Di Perri G; D'Avolio A;

Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. in Archives of virology / Arch Virol. 2015 Aug;160(8):2009-17. doi: 10.1007/s00705-015-2482-3. Epub 2015 Jun 10.
2015
ASL Città di Torino

Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A;

VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. in Pharmacogenetics and genomics / Pharmacogenet Genomics. 2015 Apr;25(4):164-72. doi: 10.1097/FPC.0000000000000123.
2015
ASL Città di Torino

Cusato J; Allegra S; Boglione L; De Nicolò A; Cariti G; Di Perri G; D'Avolio A;

Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage. in Antiviral research / Antiviral Res. 2015 Apr;116:45-7. doi: 10.1016/j.antiviral.2015.01.014. Epub 2015 Feb 7.
2015
ASL Città di Torino

Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A;

Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. in Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques / J Pharm Pharm Sci. 2015;18(2):171-6. doi: 10.18433/j3dk6t.
2015
ASL Città di Torino

Cusato J; Allegra S; De Nicolò A; Boglione L; Fatiguso G; Mohamed Abdi A; Cariti G; Di Perri G; D'Avolio A;

Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. in Antiviral therapy / Antivir Ther. 2015;20(3):335-41. doi: 10.3851/IMP2853. Epub 2014 Oct 3.
2015
ASL Città di Torino

Cusato J; Allegra S; Boglione L; De Nicolò A; Baietto L; Cariti G; Di Perri G; D'Avolio A;

Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. in Antiviral research / Antiviral Res. 2014 Sep;109:7-14. doi: 10.1016/j.antiviral.2014.06.005. Epub 2014 Jun 20.
2014
ASL Città di Torino

De Nicolò A; Boglione L; Ciancio A; Cusato J; Strona S; Cardellino CS; Abdi AM; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G; D'Avolio A;

Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. in Journal of medical virology / J Med Virol. 2014 Nov;86(11):1845-50. doi: 10.1002/jmv.24038. Epub 2014 Aug 8.
2014
ASL Città di Torino

Boglione L; Cardellino CS; De Nicolò A; Cariti G; Di Perri G; D'Avolio A;

Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. in Antiviral research / Antiviral Res. 2014 Jun;106:105-10. doi: 10.1016/j.antiviral.2014.03.016. Epub 2014 Apr 12.
2014
ASL Città di Torino

Boglione L; Cusato J; De Nicolò A; Cariti G; Allegra S; Ghisetti V; Di Perri G; D'Avolio A;

The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. in The Journal of infection / J Infect. 2014 Jul;69(1):81-7. doi: 10.1016/j.jinf.2014.02.018. Epub 2014 Mar 14.
2014
ASL Città di Torino

Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A;

Durability of the response to peginterferon-?2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting. in European journal of gastroenterology & hepatology / Eur J Gastroenterol Hepatol. 2014 Jan;26(1):52-8. doi: 10.1097/MEG.0b013e328362dc99.
2014
ASL Città di Torino
ASL Torino 3

Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Giordanino C; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G;

Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. in Antiviral research / Antiviral Res. 2014 Feb;102:35-43. doi: 10.1016/j.antiviral.2013.11.014. Epub 2013 Dec 4.
2014
ASL Città di Torino

Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A;

Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. in Journal of viral hepatitis / J Viral Hepat. 2014 Apr;21(4):260-3. doi: 10.1111/jvh.12170. Epub 2013 Sep 2.
2014
ASL Città di Torino

Boglione L; De Nicolò A; Cusato J; Cariti G; Di Perri G; D'Avolio A;

Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. in Antiviral research / Antiviral Res. 2013 Oct;100(1):114-9. doi: 10.1016/j.antiviral.2013.07.021. Epub 2013 Aug 8.
2013
ASL Città di Torino

D'Avolio A; De Nicolò A; Cusato J; Ciancio A; Boglione L; Strona S; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G;

A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. in Journal of pharmaceutical and biomedical analysis / J Pharm Biomed Anal. 2013 May 5;78-79:217-23. doi: 10.1016/j.jpba.2013.02.025. Epub 2013 Feb 27.
2013
ASL Città di Torino

D'Avolio A; De Nicolò A; Agnesod D; Simiele M; Mohamed Abdi A; Dilly Penchala S; Boglione L; Cariti G; Di Perri G;

Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia. in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology / J Clin Virol. 2013 Feb;56(2):167-9. doi: 10.1016/j.jcv.2012.10.014. Epub 2012 Nov 20.
2013
ASL Città di Torino

Boglione L; D'Avolio A; Cariti G; Di Perri G;

Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. in Journal of viral hepatitis / J Viral Hepat. 2013 Apr;20(4):e11-9. doi: 10.1111/jvh.12018. Epub 2013 Feb 18.
2013
ASL Città di Torino

Boglione L; D'Avolio A; Cariti G; Milia MG; Simiele M; De Nicolò A; Ghisetti V; Di Perri G;

Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. in Liver international : official journal of the International Association for the Study of the Liver / Liver Int. 2013 Apr;33(4):580-5. doi: 10.1111/liv.12091. Epub 2013 Jan 14.
2013
ASL Città di Torino

Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G;

Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. in Journal of pharmaceutical and biomedical analysis / J Pharm Biomed Anal. 2012 Jul;66:376-80. doi: 10.1016/j.jpba.2012.03.030. Epub 2012 Mar 28.
2012
ASL Città di Torino

D'Avolio A; De Nicolò A; Simiele M; Turini S; Agnesod D; Boglione L; Cusato J; Baietto L; Cariti G; Calcagno A; Sciandra M; Di Perri G; Bonora S;

Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. in Therapeutic drug monitoring / Ther Drug Monit. 2012 Dec;34(6):722-8. doi: 10.1097/FTD.0b013e318272e55a.
2012
ASL Città di Torino

D'Avolio A; Ciancio A; Siccardi M; Smedile A; Simiele M; Cusato J; Baietto L; Aguilar Marucco D; Cariti G; Calcagno A; Gonzalez de Requena D; Sciandra M; Troshina G; Caviglia GP; Bonora S; Rizzetto M; Di Perri G;

2012
ASL Città di Torino

D?Avolio A; Ciancio A; Siccardi M; Smedile A; Baietto L; Simiele M; Marucco DA; Cariti G; Calcagno A; de Requena DG; Sciandra M; Cusato J; Troshina G; Bonora S; Rizzetto M; Di Perri G;

Cryoglobulinemia-related vasculitis during effective anti-HCV treatment with PEG-interferon alfa-2b. in Infection / Infection. 2008 Jun;36(3):285-7. doi: 10.1007/s15010-007-6299-1. Epub 2007 Oct 25.
2008
ASL Città di Torino

De Blasi T; Aguilar Marucco D; Cariti G; Maiello A; De Rosa FG; Di Perri G;

Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. in The Journal of antimicrobial chemotherapy / J Antimicrob Chemother. 2007 Mar;59(3):565-8. doi: 10.1093/jac/dkl497. Epub 2007 Jan 9.
2007
ASL Città di Torino

Aguilar Marucco D; Veronese L; de Requena DG; Bonora S; Calcagno A; Cavecchia I; Sinicco A; De Rosa FG; Cariti G; Di Perri G;

A short course of pegylated interferon-alpha in acute HCV hepatitis. in Journal of viral hepatitis / J Viral Hepat. 2007 Feb;14(2):116-21. doi: 10.1111/j.1365-2893.2006.00802.x.
2007
ASL Città di Torino

Calleri G; Cariti G; Gaiottino F; De Rosa FG; Bargiacchi O; Audagnotto S; Quaglia S; De Blasi T; Romano P; Traverso A; Leo G; Carbone R; Del Mastro B; Tinelli M; Caramello P; Di Perri G;

Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial. in Italian journal of gastroenterology and hepatology / Ital J Gastroenterol Hepatol. 1998 Apr;30(2):181-4.
1998
ASL Città di Torino

Calleri G; Colombatto P; Gozzelino M; Chieppa F; Romano P; Delmastro B; Macor A; Cariti G; Brunetto MR; Grillone W; Bonino F;

©2024 Tutti i diritti riservati. Biblioteca Virtuale per la Salute - Piemonte